A long-term follow-up study on patient outcomes, including fibrosis stage, hepatic decompensation, cirrhosis, HCC, and other comorbidities, is required to assess ANA pattern changes after HCV eradication. This evidence concerns the gene BTG3 and hepatocellular carcinoma.